|
|
Volumn 497, Issue 7451, 2013, Pages 544-
|
|
Immunotherapy's cancer remit widens
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
IPILIMUMAB;
NIVOLUMAB;
ADVANCED CANCER;
CANCER IMMUNOTHERAPY;
DRUG COST;
HEALTH CARE COST;
HUMAN;
KIDNEY CANCER;
LUNG CANCER;
MEDICAL RESEARCH;
MELANOMA;
NOTE;
PRIORITY JOURNAL;
STOMACH CANCER;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
COMBINED MODALITY THERAPY;
DRUG THERAPY, COMBINATION;
HUMANS;
IMMUNOTHERAPY;
NEOPLASMS;
|
|
EID: 84878386724
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/497544a Document Type: Note |
|
Times cited : (42)
|
|
References (0)
|
